Literature DB >> 15013046

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide.

Ronald N Jones1, Jennifer M Streit, Thomas R Fritsche.   

Abstract

Results from dalbavancin dry-form commercial broth microdilution MIC panels (Sensititre, TREK Diagnostics) were compared with reference frozen-form MIC values to assure the validity and reproducibility of the extended shelf-life product. A collection of 402 organisms from four major organism groups were used in the validation trial and 10 strains for reproducibility replicate tests. A total of 98.6% commercial dalbavancin MIC results were within +/-1 log(2) dilution of reference values (76.2% were identical) and reproducibility trials produced identical MIC results in 88.9-92.2% of dalbavancin MIC comparisons. These dalbavancin MIC results demonstrated the acceptable accuracy of commercially-prepared broth microdilution products for use in subsequent clinical trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013046     DOI: 10.1016/j.ijantimicag.2003.07.008

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  10 in total

1.  Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms.

Authors:  Thomas R Fritsche; Robert P Rennie; Beth P Goldstein; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  Bactericidal activity and resistance development profiling of dalbavancin.

Authors:  Beth P Goldstein; Deborah C Draghi; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.

Authors:  Douglas J Biedenbach; James E Ross; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

4.  Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.

Authors:  Ronald N Jones; Helio S Sader; Thomas R Fritsche; Patricia A Hogan; Daniel J Sheehan
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

5.  Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.

Authors:  Jordan R Smith; Katie E Barber; Jessica Hallesy; Animesh Raut; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

6.  Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination.

Authors:  Ronald N Jones; Nicole M Holliday; Kevin M Krause
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

Review 7.  New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

Authors:  Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita
Journal:  Antimicrob Agents Chemother       Date:  2022-04-27       Impact factor: 5.938

8.  Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Authors:  Francis F Arhin; Ingrid Sarmiento; Adam Belley; Geoffrey A McKay; Deborah C Draghi; Parveen Grover; Daniel F Sahm; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

9.  Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.

Authors:  Douglas J Biedenbach; Jan M Bell; Helio S Sader; John D Turnidge; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2009-01-05       Impact factor: 5.191

10.  Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

Authors:  Ronald N Jones; Jason E Schuchert; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.